Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific share repurchase transaction executed on July 21, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,350,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,351.5 pence per share; lowest price paid was 1,337.5 pence per share.
- Treasury Holdings (Settled): 486,284,284 shares (8.68% of total issued share capital).
- Treasury Holdings (Including Unsettled): 490,504,284 shares (9.59% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,117,235,200 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,350,000 shares on July 21, 2011. This transaction increased the Company's treasury share holdings to approximately 9.59% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intent is to hold the purchased shares in Treasury.
Investor Verification Checklist
- Verify the total cost of the 1,350,000 shares purchased on July 21, 2011, based on the reported price range.
- Confirm the settlement status of the 4,220,000 shares included in the "unsettled" treasury count.
- Review the remaining authorization for share repurchases under the mandate granted on May 5, 2011.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) calculations.